Introduction

Michael Schatz; Amin Antoine Nabih Kazzi; Barry Brenner; Carlos A. Camargo; Thomas Corbridge; Jerry A. Krishnan; Richard Nowak; Gary Rachelefsky

doi:10.1016/j.jemermed.2009.06.104

Introduction

Michael Schatz^*, Amin Antoine Nabih Kazzi, Barry Brenner, Carlos A. Camargo, Thomas Corbridge, Jerry A. Krishnan, Richard Nowak, Gary Rachelefsky

^*Corresponding author for this work

Medicine, Pulmonary Division

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	S1-S5
Journal	Journal of Emergency Medicine
Volume	37
Issue number	2 SUPPL.
DOIs	https://doi.org/10.1016/j.jemermed.2009.06.104
State	Published - Aug 2009

Funding

Disclosure of potential conflict of interest: M. Schatz has been a consultant for GlaxoSmithKline and has received research support from Aerocrine, Genentech, GlaxoSmithKline and Merck. A. A. N. Kazzi has declared that he had no conflict of interest. B. Brenner has declared that he had no conflict of interest. C. A. Camargo Jr has been a consultant, speaker, or advisory board member for AstraZeneca, Critical Therapeutics, Dey, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering-Plough and has received research support from the National Institutes of Health, AstraZeneca, Critical Therapeutics, GlaxoSmithKline, Merck, Novartis, and Respironics. T. Corbridge is on the speakers' bureau for GlaxoSmithKline. J. A. Krishnan has declared that he had no conflict of interest. R. Nowak has declared that he had no conflict of interest. G. Rachelefsky has been a speaker or advisory board member for AstraZeneca, Schering-Plough, CSL Behring, Merck, and Sanofi Aventis and has provided legal consultation or expert witness testimony on the topic of environmental injuries, mostly mold-related.

ASJC Scopus subject areas

Emergency Medicine

Access to Document

10.1016/j.jemermed.2009.06.104

Cite this

@article{9f469a1ad6a74630beb10f37bbaad2c9,

title = "Introduction",

author = "Michael Schatz and Kazzi, {Amin Antoine Nabih} and Barry Brenner and Camargo, {Carlos A.} and Thomas Corbridge and Krishnan, {Jerry A.} and Richard Nowak and Gary Rachelefsky",

note = "Funding Information: Disclosure of potential conflict of interest: M. Schatz has been a consultant for GlaxoSmithKline and has received research support from Aerocrine, Genentech, GlaxoSmithKline and Merck. A. A. N. Kazzi has declared that he had no conflict of interest. B. Brenner has declared that he had no conflict of interest. C. A. Camargo Jr has been a consultant, speaker, or advisory board member for AstraZeneca, Critical Therapeutics, Dey, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering-Plough and has received research support from the National Institutes of Health, AstraZeneca, Critical Therapeutics, GlaxoSmithKline, Merck, Novartis, and Respironics. T. Corbridge is on the speakers' bureau for GlaxoSmithKline. J. A. Krishnan has declared that he had no conflict of interest. R. Nowak has declared that he had no conflict of interest. G. Rachelefsky has been a speaker or advisory board member for AstraZeneca, Schering-Plough, CSL Behring, Merck, and Sanofi Aventis and has provided legal consultation or expert witness testimony on the topic of environmental injuries, mostly mold-related. ",

year = "2009",

month = aug,

doi = "10.1016/j.jemermed.2009.06.104",

language = "English (US)",

volume = "37",

pages = "S1--S5",

journal = "Journal of Emergency Medicine",

issn = "0736-4679",

publisher = "Elsevier Inc.",

number = "2 SUPPL.",

}

TY - JOUR

T1 - Introduction

AU - Schatz, Michael

AU - Kazzi, Amin Antoine Nabih

AU - Brenner, Barry

AU - Camargo, Carlos A.

AU - Corbridge, Thomas

AU - Krishnan, Jerry A.

AU - Nowak, Richard

AU - Rachelefsky, Gary

N1 - Funding Information: Disclosure of potential conflict of interest: M. Schatz has been a consultant for GlaxoSmithKline and has received research support from Aerocrine, Genentech, GlaxoSmithKline and Merck. A. A. N. Kazzi has declared that he had no conflict of interest. B. Brenner has declared that he had no conflict of interest. C. A. Camargo Jr has been a consultant, speaker, or advisory board member for AstraZeneca, Critical Therapeutics, Dey, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering-Plough and has received research support from the National Institutes of Health, AstraZeneca, Critical Therapeutics, GlaxoSmithKline, Merck, Novartis, and Respironics. T. Corbridge is on the speakers' bureau for GlaxoSmithKline. J. A. Krishnan has declared that he had no conflict of interest. R. Nowak has declared that he had no conflict of interest. G. Rachelefsky has been a speaker or advisory board member for AstraZeneca, Schering-Plough, CSL Behring, Merck, and Sanofi Aventis and has provided legal consultation or expert witness testimony on the topic of environmental injuries, mostly mold-related.

PY - 2009/8

Y1 - 2009/8

UR - http://www.scopus.com/inward/record.url?scp=68349162732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349162732&partnerID=8YFLogxK

U2 - 10.1016/j.jemermed.2009.06.104

DO - 10.1016/j.jemermed.2009.06.104

M3 - Article

C2 - 19683660

AN - SCOPUS:68349162732

SN - 0736-4679

VL - 37

SP - S1-S5

JO - Journal of Emergency Medicine

JF - Journal of Emergency Medicine

IS - 2 SUPPL.

ER -

Introduction

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this